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Abstract. Background: NRAS mutations
in hematologic malignancies, especially in those of myeloid origin.
Objective: We aimed to determine the frequency of NRAS (NRAS
significance in Egyptian children with acute myelogenous leukemia (AML).
Subject and methods: Peripheral blood and bone marrow (BM) samples were taken from 39 de novo 
pediatric AML patients.  Twenty  subjects with  matched age and  sex  were selected as  a  control 
group.  Samples  from  patients  an
genomic PCR-SSCP method.  
Results: NRAS mutations at the time of diagnosis was found in 6/39 (15.4%) AML cases. Patients 
with  NRAS
mutant had  no  significant  improved  clinical  outcome  than  patients  w
Patients with NRAS
mutant had similar complete remission (CR) rates compared with non
patients  (66.7%  vs.  69.5%,  P=0.43).
presence of NRAS
mutant (RR 33.4% vs. 30.2%, P=0.26).
overall survival (OS) was associated with the presence of NRAS mutations. This adverse prognosis 
associated  with  NRAS  mutations  was  also  observed  in  terms  of  disease
(P=0.007).  Univariate  analysis  showed  that  unfavorable  prognostic  factors  for  DFS  were 
cytogenetic data (P = 0.005) and the NRAS gene mutation (P = 0.002). 
Conclusion: NRAS
mutant did not contribute to increase the disease recurrence, however NRAS
was found to be a poor prognostic factor for children with AML. Further studies to confirm these 
findings are required because of the small number of patients with NRAS mutation.
Introduction. Acute  myeloid  leukemia  (AML)  is 
characterized  by  expansion  of  myeloid  blasts  with 
; Open Journal System 
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: NRAS mutations are the most commonly detected molecular abnormalities
in hematologic malignancies, especially in those of myeloid origin.
We aimed to determine the frequency of NRAS (NRAS
mutant) mutation; and its prognostic 
with acute myelogenous leukemia (AML).
Peripheral blood and bone marrow (BM) samples were taken from 39 de novo 
pediatric AML patients.  Twenty  subjects with  matched age and  sex  were selected as  a  control 
group.  Samples  from  patients  and  control  were  analyzed  for  Exons  1,  2  of  NRAS  gene  using 
NRAS mutations at the time of diagnosis was found in 6/39 (15.4%) AML cases. Patients 
had  no  significant  improved  clinical  outcome  than  patients  w
had similar complete remission (CR) rates compared with non
patients  (66.7%  vs.  69.5%,  P=0.43). Those  in  CR  had  a  similar relapse  rate regardless  of  the 
(RR 33.4% vs. 30.2%, P=0.26).  However, an adverse prognosis for 3 year 
overall survival (OS) was associated with the presence of NRAS mutations. This adverse prognosis 
associated  with  NRAS  mutations  was  also  observed  in  terms  of  disease
sis  showed  that  unfavorable  prognostic  factors  for  DFS  were 
cytogenetic data (P = 0.005) and the NRAS gene mutation (P = 0.002). 
did not contribute to increase the disease recurrence, however NRAS
stic factor for children with AML. Further studies to confirm these 
findings are required because of the small number of patients with NRAS mutation.
Acute  myeloid  leukemia  (AML)  is 
characterized  by  expansion  of  myeloid  blasts  with 
suppression of normal hematopoiesis. Cytogenetic and 
molecular  studies  have  defined  AML  as  a 
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Peripheral blood and bone marrow (BM) samples were taken from 39 de novo 
pediatric AML patients.  Twenty  subjects with  matched age and  sex  were selected as  a  control 
d  control  were  analyzed  for  Exons  1,  2  of  NRAS  gene  using 
NRAS mutations at the time of diagnosis was found in 6/39 (15.4%) AML cases. Patients 
had  no  significant  improved  clinical  outcome  than  patients  without  mutation. 
had similar complete remission (CR) rates compared with non-mutated 
Those  in  CR  had  a  similar relapse  rate regardless  of  the 
However, an adverse prognosis for 3 year 
overall survival (OS) was associated with the presence of NRAS mutations. This adverse prognosis 
associated  with  NRAS  mutations  was  also  observed  in  terms  of  disease-free  survival  (DFS) 
sis  showed  that  unfavorable  prognostic  factors  for  DFS  were 
did not contribute to increase the disease recurrence, however NRAS
mutant
stic factor for children with AML. Further studies to confirm these 
findings are required because of the small number of patients with NRAS mutation.
suppression of normal hematopoiesis. Cytogenetic and 
molecular  studies  have  defined  AML  as  a Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
heterogeneous  disease.
1 The  presence  of  defined 
karyotypes  is  among  the  most  important  prognostic 
factors in  acute myeloid leukemia  (AML). However, 
even  within  defined  cytogenetic  groups  stability  of 
remission  and  long-term  survival  may  vary 
significantly.  Therefore,  additional  recurrent 
aberrations may have a prognostic impact.
2 It has been 
showed that Pediatric AML patients may harbor more 
than one mutation at diagnosis, some of which with a 
possible prognostic impact.
3-7 Mutations in the NRAS
gene are one of these genetic aberrations that play a 
role in myeloid neoplasia.
8
NRAS  gene  plays  an  important  role  in  the 
regulatory  processes  that  govern  proliferation, 
differentiation and apoptosis;
9 abnormality in this gene 
has been implicated in the pathogenesis of AML. RAS 
oncogenes  encode  a  family  of  membrane-associated 
proteins,  which  regulate  signal  transduction  upon 
binding to a variety of membrane receptors.
10 There are 
three  functional  RAS  genes  (NRAS,  KRAS  and 
HRAS); in AML. K-RAS mutation occurs to a lower 
but  still  significant  frequence  in  pediatric  AML.
11
NRAS is the most prominent; reported in 11%-30% of 
patients.
12 All  homologs  were  exclusively  in  codons 
12, 13, and 61 conferring constitutive activation of the 
RAS protein, which is subsequently held in the GTP 
bound  status  leading  to  an  increased  activity  of  the 
RAS pathway causing an increased proliferation and a 
decreased  apoptosis  rate.
13 RAS  mutations  were 
described  in  the  various  solid  tumors  as  well  as  in 
hematologic  malignancies.  The  prognostic  impact  of 
NRAS mutations is still under research and seems to 
vary from disease to disease,
14 several studies indicated 
a  poor  prognostic  impact  for  that  mutation,
14,15 and 
however  Lapillonne  et  al  confirmed  this  finding  in 
pediatric AML.
16 On the contrary, Neubauer et al found 
a  favorable  outcome  for  malignancies  with  NRAS 
mutations,
12 and  some  studies  failed  to  define  any 
prognostic impact for NRAS mutations.
10,13,17
We undertook this study to determine the frequency 
of NRAS mutation and its prognostic significance in a 
number of Egyptian pediatric patients with AML.
Patients  and  Methods.  Newly  diagnosed  pediatric 
AML patients were included in this study; cases were 
recruited  from  pediatric  hematology  clinics  of  Tanta 
University  Hospitals,  Tanta,  Egypt.  Peripheral  blood 
and BM samples were obtained from 39 de novo AML 
cases at initial diagnosis obtaining an informed consent 
from patients or their guardians; they were 21 boys and 
18 girls. The median age was 7.4 years (range, 5.6-13 
years). The  median percentage  of  blasts  in  the  fresh 
bone marrow samples was (65%). All included patients 
were receiving the same treatment protocol approved 
by the  Oncology Team of  Tanta  University Hospital 
TUH; in brief they received 1-2 cycles of 14-21 days of 
intensively  timed  induction  chemotherapy 
(doxorubicin, Ara-C, 6-thioguanine and methotrexate) 
depending upon BM aspiration done at the end of each 
induction  course.  Additional  consolidation  regimens 
included  1-2  cycles  of  12-days  (doxorubicin,  Ara-C, 
VP-16 and methotrexate). Then patients who did not 
achieve remission received intermittent chemotherapy 
(Ara-C,  6-thioguanine  and  methotrexate)  every  3 
months for 6 cycles with the standard follow-up care 
and regular BM aspiration every 21 days to confirm 
remission;  complete  remission  means normocellular 
bone  marrow  contain  less  than  5%  blast  cells  and 
showing evidence of normal maturation of other bone 
marrow  elements  as  evidenced  by  the  repeated  BM 
aspiration.  The  average  duration  of  follow  up  was 
mean ± SD (32 ± 2.24 months).
Patients  were  classified  according to  the  standard 
methods; morphological according FAB classification, 
cytochemical  and  immunological  evaluation.
13
Informed consent was obtained from twenty subjects 
with  matched  age  and  sex  who  were  selected  as  a 
control group. Samples from patients and control were 
analyzed for mutation in Exons 1, 2 of the NRAS gene 
using genomic PCR method. 
Cytogenetic Analysis. Cytogenetic investigations were 
performed  by  karyotyping  G-banding  analysis  in  all 
patients.
18
PCR  of NRAS Gene.  Genomic  DNA was  extracted 
from  diagnostic  bone  marrow  specimens  of  patients 
and control using the QIAamp DNA blood mini kit for 
DNA  extraction  provided  by  QIAGEN  (Inc 
Chasworthy, CA). The concentration of extracted DNA 
was then measured by UV spectrophotometry at 260 & 
280  nm  and  analyzed  by  electrophoresis  on  2%  
agarose gel for detection of purity.
Separate  assays  were  developed  for  mutation 
detection at (hot spots) in codons 12/13 (exon 1) and 
codon 61 (exon 2). Oligonucleotide primers amplifying 
short  fragments  {241 base  pair  (bp)  for  exon  1  and 
201 bp for exon 2} were designed for PCR as follows:
N12/13  assay. forward,  5'-
GACTGAGTACAAACTGGTGG-3';  and  reverse,  5'-
TGCATAACTGAATGTATACCC-3'. 
N61  assay. forward,  5' 
CAAGTGGTTATAGATGGTGAAACC-3';  and 
reverse,  5'-
AAGATCATCCTTTCAGAGAAAATAAT-3'.
PCR amplification was performed in 50 ul reaction, 
contained 50-100 ng of genomic  DNA, 10  mM Tris 
HCl (pH 8.3), 50 mM KCl and 1.5 mM Mg Cl2, 200 
uM of each deoxyribonucleotide triphosphate (dNTP), 
2.5 units Taq polymerase, and 6% dimethylsulphoxide. Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
PCR  conditions  were  as  follows:  (1)  Exon  1, 
HotStarTaq  (Qiagen,  Valencia,  CA),  and  0.625 U. 
Primers (12.5 pmol), N12/13 forward, N12/13 reverse. 
Denaturing,  95  C  for  15  minutes  and  94°C  for  30 
seconds;  annealing,  55.5°C  for  1minute;  extension, 
72°C for 1 minute for 35 cycles; final cycle at 72°C for 
10 minutes. (2) Exon 2, HotStarTaq (Qiagen), 0.625 U. 
Primers  (12.5  pmol),  N61F  forward,  N61R  reverse. 
Denaturing, 95°C for 15 minutes; 94°C for 30 seconds; 
annealing, 55.5°C for 1 minute; extension, 72°C for 1 
minute  for  35  cycles;  final  cycle  at  72°C  for  10 
minutes.
Single-strand conformation polymorphism (SSCP) was 
performed  to  PCR  product  to  detect  mutations. 
Products  were  mixed  with  10  volumes  of  loading 
buffer,  quenched on  ice  immediately,  and  applied to 
5%  polyacrylamide  gel  electrophoresis  at  50  V, 
overnight,  stained  by  silver  nitrates  and  wrapped  in 
plastic  foil.  Normal  gene  exhibits  a  specific 
conformational  pattern,  while  mutant  gene  displays 
pattern  with  different  electrophoretic  mobility 
(mobility  shift)  which  was  confirmed  by  repeated 
SSCP (Figure 1).
Statistical  Methods.  Data  were  processed  and 
analyzed using SPSS for windows version 16.0 (SPSS, 
Inc,  Chicago,  IL,  USA). Qualitative  data  were
expressed as frequency and percentage and quantitative 
data  were  expressed  as  median.  Chi-square  test  was 
used  for  comparative  analysis.  The  prevalence  of 
NRAS  mutations  in  AML  was  too  low  to  permit 
statistical  analysis  for  correlation  with  survival. 
Kaplan-Meier  analysis  was  used  for  survival  of 
patients.  The  prognostic  significance  of  the  clinical
variables  was  assessed  using  the  Cox  proportional 
hazards model. For all analyses, the P values were two-
tailed, and a P value of less than 0.05 was considered 
statistically significant.
Figure 1. SSCP of PCR products from NRAS exon 1. C, normal 
marrow control, 1-6, samples from different pediatric patients. High 
molecular weight bands in lines 3 and 5 represent a normal NRAS 
band and a mutant band. Lines 1, 2, 4 and 6 represent wild type 
NRAS.
Table 1. NRAS mutations and clinical characteristics in pediatric 
AML cases
No RAS 
mutation (n=33)
RAS mutation 
(n=6) P
Age(median) 6,5 9,5 0,82
Leukocyte x10
3/µL 
(median) 40,1 42,5 0,92
Bone marrow 
blast%(median) 70,2 58 0,04
Peripheral blast% 
(median) 55,4 34 0,01
Results.  Mutant band in addition to wild bands were 
found  in  6  (15.4%)  of  39  pediatric  AML  patients, 
whereas  33  had  only  the  NRAS wild-type  allele 
(NRAS
wild). No  apparent  clinical  or  biologic 
characteristics  were  significantly  different  for  the 
patients  with  NRAS  gene  mutations  when  compared 
with those without NRAS mutations except that  there 
was  lower peripheral and bone marrow blast (P=0.01, 
P=0.04)  in  patients  with  NRAS  mutation  when 
compared with those without  mutation (Table 1). 
Patients were assigned to the following cytogenetic 
groups: t(8;21) (15.4%; 6/39), inv(16) (15.4%6/39),del 
5 (5.1%;2/39), del 7 (2.6%;1/39); and with CN-AML 
(53.8%;  21/39).  In  7.7%  (3/39)  of  the  cases, 
conventional karyotyping was not available (Table 2).
Patients with Inv(16) is presented with highest  WBC 
count(median  41  x10
3/µL),  and  t(8;21)AML  patients 
with  lowest  WBCs  (median  18  x10
3/µL)  compared 
with  the  other  cytogenetic  groups  (Table  2).  The 
median ages of children with Inv (16) AML (7 years), 
with t(8;21) (8.3 years) , with del(7) (8.5), and with del 
5(8.9  years)  were  younger  compared  with  CN-AML 
(9.5 years).
In the  FAB  subtype  M4e, NRAS mutations  were 
represented more frequently (50%, 3 of 6) than they 
were in all other subtypes. Inthe M3, M5, M6 and M7 
subtypes,  no  NRAS  mutation  was  detected,  making 
NRAS  mutations  highly  underrepresented  in  these 
subtypes. In all other FAB subtypes, the distribution of 
NRAS mutations did not differ significantly from each 
other. A detailed distributionof NRAS mutations in the 
Table  2. Clinical  characteristics  according  to  cytogenetic 
aberrations 
Cytogenetic Frequency Age(year) WBCs (x10
3/µL)
N=39 N. (%) median Median
t(8;21) 6 (15.4%) 8.3 18
inv(16) 6 (15.4%) 7.0 41
del(5) 2 (5.1%) 8.9 34
del(7) 1 (2.6%) 8.5 32
CN 21(53.8%) 9.5 38
Not done 3 (7.7%) 9.0 29
CN: cytogenetic normalMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 3. Frequency  of  NRAS  mutation  according  to  FAB  and 
cytogenetics
                                    RAS mutation NO RAS mutation
Cytogenetic (n= 6) (n= 33)
Good-risk group
t(8;21) 1 5
t(inv16) 2 4
Poor-risk group
del(5) 0 2
del(7) 0 1
Normal group                              
normal karyotype 3 18
Not done 0 3
FAB
M1 1 8
M2 1 11
M3 0 2
M4 1 4
M4e 3 3
M5 0 2
M6 0 1
M7 0 2
respective FAB subtypes is presentedin Table 3.
Based on cytogenetic findings, the 39 patients were 
segregated into three groups: a good-risk group (n =12) 
was defined by karyotype, t(8;21) or inv(16); a poor-
risk group (n =3) by del(5) or del(7) and standard-risk 
group (n =21) by normal  karyotypes.
Based  on  the  previous  findings,  we  analyzed  the 
influence  of  NRAS  mutations  on  the  prognosis  of 
pediatric  AML  patients for  whom  clinical  follow  up 
data  were  available.  Table  4 shows  the  clinical 
outcome in pediatric AML patients. In the total group, 
there  was  no difference  with  regard  to  CR  rate 
(NRAS
mutant,  66.7%;  NRAS
wild,  69.5%;  P  =  0.43). 
Relapse was significantly more frequent in the AML 
patients with NRAS gene mutations (NRAS
muant, 33.4 
%; NRAS
wild, 30.2 %; P= 0.26).
At 3 years, the estimated OS was 30±15% in the
Table 4. NRAS mutation and clinical outcome
Patients No RAS 
mutation
RAS 
mutation P
All (n=39)
  CR(%) 69.5 66.7 0.43
  RR(%) 30.2 33.4 0.26
  3-year OS(%) 62 30 0.01
  3-year DFS(%)    59 35 0.007                
Figure 2. DFS in children with AML according to NRAS mutation.
Figure 3. OS according to NRAS mutation.
presence  of  an  NRAS  mutation  and  62±5%  in  its 
absence (P= 0.01). Adverse prognosis associated with 
N-ras mutations was observed in terms of 3 years DFS 
(NRAS
mutant 35% vs NRAS
wild 59%, P= 0.007), (Figure 
2 and 3).
Univariate analysis showed that unfavorable prognostic 
factors for DFS were cytogenetic data (P = 0.005) and 
NRAS  mutation  (P  =  0.002) (Table  5).  Multivariate 
analysis showed NRAS was the strongest unfavorable 
factor (relative risk [RR], 3.6; P = 0.007), followed by 
cytogenetics (P = 0.02). 
Discussion. In recent years, a major focus of molecular 
cancer research has been the analysis of genes that may 
be  causative  in  carcinogenesis  (oncogenes).  The 
clinical  significance  of  RAS  mutations  has  not  been 
uniformly  established.  In  the  current  study,  we 
evaluated the clinical significance of NRAS mutations 
and investigated NRAS
mutant by genomic PCR method 
in 39 newly diagnosed pediatric AML cases. Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table  5. Unvafourable  prognostic  factors  for  3-year  DFS  in 
pediatric AML who achieved CR
Prognostic factors Univariate Multivariate
P value          P value RR 95% CI
Age (years)
  10 years or older 0.3 0.2 2.1 1.2-6.5
FAB 
  Other than M7 0.1 0.3 3.2 1.6-5.4
*Cytogenetic 
   0.005 0.02 2.4 0.97-6.2
NRAS mutation
   0.002 0.007 3.6 1.5-8.5
Activated RAS  mutations confer  proliferative and 
survival  signals.  Mutations  in  the  NRAS  gene  are 
frequent genetic aberrations in adult AML.
19 However, 
there  have  been  only  a  few  studies  on  childhood 
AML.
20 With  different  mutation-detection  techniques 
used and heterogeneous patient populations studied, the 
reported  incidence  of  NRAS
mutant in  patients  with 
childhood AML at presentation vary considerably; in 
our study 15.4% of pediatric AML patients (6/39) had 
NRAS
mutant,  corresponding  to  the  reported  frequency  
by others.
15,21 Primary analyses revealed a statistically 
significant  association  between  peripheral  and  bone 
marrow  blast  counts  and  NRAS mutation 
(P=0.01,P=0.04  respectively),  however  no  significant 
differences  had  been  found  between  the  two  groups 
with respect to age, gender, platelet count and WBCs 
count.  These  findings  are  in  agreement  with  those 
reported in literatures.
10,13
The highest frequency (33.3%) of NRAS mutations 
in our cohort (2/6) compared with the total cohort was 
detected in patients with inv(16). The high incidence of 
NRAS mutations in inv(16) in our study corresponded 
with most of the previously published studies reporting 
frequencies  of  26%  to  33%  (22,23).  11q23/MLL 
aberrations  are  a  frequent  abnormality  in  pediatric 
AML.
24,25,26 The frequency of 11q23/MLL-rearranged 
AML may have been underestimated because of low 
number of cases in the included study and because in 
our study as well as in other studies performed in the 
past,  the  cryptic  MLL  rearrangements  may  be  not 
detected by conventional karyotyping. It is conceivable 
that  the  biological  differences  may  lead  to  different 
treatment  strategies  for  these  age  categories  in  the 
future.
27 In our study, oldest children with AML were 
characterized  by  a  high  frequency  of  normal 
cytogenetic (53.8%) but the very young in the included 
study are characterized by higher frequency of inv (16). 
The prognosis of AML depends on factors such as 
age,  initial  leukocyte  count,  FAB  classification, 
karyotype,  immune  phenotype,  and  response  to 
remission-induction therapy.
28,29 Our study showed that 
cytogenetic was unfavorable prognostic factor among 
AML  patients  by  univariate  analysis.  This  was  in 
agreement with other study who found that cytogenetic 
data  is  thought  to  be  the  most  important  prognostic 
factor for AML.
30
The prognostic significance of NRAS mutation in 
both  adults and children remains  disputed. Generally 
NRAS  gene  mutation  is  associated  with  tumor 
progression  and  was  reported  to  be  associated  with 
poor prognosis in solid tumors and acute lymphoblastic 
leukemia (ALL).
31,32 Published reports addressing the 
clinical  significance  of  NRAS  mutations  in  patients 
with  acute  myeloid  leukemia  are  inconclusive. 
Whereas  some  studies  demonstrated  a  beneficial 
clinical effect of NRAS mutations,
33,34 others reached a 
different  conclusion  (e.g.  lower  CR).
35 Other  studies 
also  did  not  that  show  that  patients  with  NRAS
mutations had significantly good outcomes.
36,37
In this study, the presence of NRAS gene mutation  
was related to  similar complete remission (CR) rates 
following induction chemotherapy compared with non-
mutated patients (66.7% vs. 69.5%, P=0.43). Those in 
CR had a similar relapse rate regardless of the presence 
of  NRAS mutations (RR 33.4%  vs. 30.2%, P=0.26). 
However,  the  presence  of  NRAS  mutations  was 
associated  with  poor  three  years  OS  and  DFS 
compared  with  wild  type  cases  (OS,  P=0.01;  DFS, 
P=0.007).    This  discrepancy  between  these  studies 
findings and our study may be explained by differences 
in  the  intensity  of  the  chemotherapy  protocols 
employed to treat this group of patients and the small 
number of our cases.
Conclusions. In addition to the evidence that activation 
of  the  RAS-signaling  cascade  contributes  to  the 
molecular pathogenesis of myeloproliferative disorders 
(38),  NRAS  mutation  has  adverse  prognostic  impact 
but further pediatric studies will be necessary to extend 
our  knowledge  and  more  precisely  define  the 
prognostic significance of NRAS mutations. This study 
also  demonstrates  the  need  to  screen  for  specific 
translocation  partners  to  allow  appropriate  treatment 
stratification like WT1 and FLT3. 
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